(NASDAQ: PSTV) Plus Therapeutics's forecast annual revenue growth rate of 103.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Plus Therapeutics's revenue in 2026 is $5,182,000.On average, 6 Wall Street analysts forecast PSTV's revenue for 2026 to be $45,552,396, with the lowest PSTV revenue forecast at $26,981,776, and the highest PSTV revenue forecast at $81,668,053. On average, 6 Wall Street analysts forecast PSTV's revenue for 2027 to be $134,385,762, with the lowest PSTV revenue forecast at $67,454,439, and the highest PSTV revenue forecast at $202,363,316.
In 2028, PSTV is forecast to generate $318,109,627 in revenue, with the lowest revenue forecast at $270,960,351 and the highest revenue forecast at $368,590,326.